Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial

Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals drug, razuprotafib. Razuprotafib was chosen for testing in the I-SPY COVID Trial because it is hypothesized to stabilize and repair the blood vessels in the lung and improve gas exchange.
HHS, DOD engage Quantum Leap Healthcare Collaborative in search for effective treatments for the sickest COVID-19 patients

In the race to identify safe and effective therapeutic treatments for the sickest COVID-19 patients, the U.S. Department of Health and Human Services and the Department of Defense are engaging a non-profit research organization, Quantum Leap Healthcare Collaborative of San Francisco, on a phase 2 clinical trial that rapidly screens multiple potential drugs simultaneously.
Susan G. Komen® Recognizes Renowned Investigators as 2020 Recipients of Brinker Awards for Scientific Distinction

Susan G. Komen®, the world’s leading breast cancer organization, recognized two widely respected and innovative breast cancer researchers this week, announcing that Donald McDonnell, Ph.D., and Laura Esserman, M.D., have been selected as this year’s recipients of the Brinker Awards – Komen’s highest scientific honor.
Laura Esserman, MD, Co-founder of Quantum Leap Healthcare Collaborative and Professor at UCSF, will speak at the TIME 100 Health Summit

Quantum Leap Healthcare Collaborative is pleased to announce that co-founder Dr. Laura Esserman will be among the speakers of the first-ever TIME 100 Health Summit, which will convene individuals from the TIME 100 community and prominent figures in healthcare to highlight essential perspectives on health and wellness, and to encourage cross-disciplinary collaboration toward a better, healthier world.